SCHAUMBURG, Ill., March 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefepime for injection, USP, a broad ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI. Positive results were announced from a phase 3 study evaluating ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

The FDA has approved the use of B. Braun Medical's Duplex drug delivery system for delivery of FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP. Cefepine is used in ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

Cefepime is a β-lactam antibiotic that is cleared through the kidneys. Elimination of cefepime is considerably delayed in patients with impaired renal function, and cefepime has been reported to have ...

Among the top stories in infectious disease this past week was the CDC reporting that an estimated 6 million to 7 million Americans have become ill from influenza thus far this season and the FDA ...

A total of 11 men and 1 woman between the ages of 18 and 70 years (mean ± S.D., 33 ± 15 years) were included in the cefepime group. One of the 12 patients underwent two courses of cefepime therapy, so ...